RxDoctor Payments Data

Goetz Kloecker, MD

Hematology & Oncology · Louisville, KYNPI 1306827126

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $466,313 of the $583,985 with a category attached, or 79.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 23.4%. Among hematology & oncology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$583,985in general payments, 2019–2025

Across 982 payments — averaging $594.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$137K
  • E.r. Squibb & Sons, L.L.C.$80K
  • Regeneron Healthcare Solutions, Inc.$60K
  • Genentech USA, Inc.$47K
  • Jazz Pharmaceuticals Inc.$47K
  • Merck$37K
  • plus $176K from 54 others
$594,166in research payments, 2019–2025

Across 26 payments — averaging $22,853 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$333K
  • E.r. Squibb & Sons, L.L.C.$76K
  • Amgen$52K
  • Novocure Inc.$51K
  • Mirati Therapeutics, Inc.$49K
  • Genentech, Inc.$30K
  • plus $4K from 2 others

What the payments were for

  • Consulting fees$62,44811%
  • Speaking & faculty fees$466,31380%
  • Travel & lodging$27,3175%
  • Food & beverage$27,6665%
  • Education$2410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)106$136,909
E.r. Squibb & Sons, L.L.C.93$79,639
Regeneron Healthcare Solutions, Inc.84$60,378
Genentech USA, Inc.48$47,135
Jazz Pharmaceuticals Inc.42$46,581
Merck96$36,964
Lilly USA, LLC39$32,791
Amgen55$24,872
Sanofi38$22,715
EMD Serono, Inc.14$19,373
Mirati Therapeutics, Inc.25$19,030
Novartis68$12,397
Dova Pharmaceuticals2$9,330
Daiichi Sankyo Inc.51$7,868
Bayer13$5,464
Novocure Inc.6$3,249
Bristol Myers Squibb(2 entities)12$2,807
AbbVie10$2,355
Regeneron2$2,083
Gilead(2 entities)9$1,968
Eisai Inc.3$1,904
Eli Lilly1$1,400
Puma Biotechnology, Inc.7$1,219
Pfizer21$913
Johnson & Johnson16$633
Incyte Corporation20$499
Coherus Oncology, Inc.6$451
Recordati_rare_diseases_inc.5$305
Boehringer Ingelheim8$260
Adaptive Biotechnologies Corporation5$247
Beigene USA, Inc.5$236
Foundation Medicine, Inc.5$197
Iovance Biotherapeutics, Inc.1$196
GSK4$178
Ipsen Biopharmaceuticals, Inc2$141
Stemline Therapeutics Inc.6$128
Exelixis Inc.1$120
Pharmacyclics LLC, An Abbvie Company4$92
Rigel Pharmaceuticals, Inc.4$84
Array Biopharma Inc6$83
Seagen Inc.4$72
Takeda Pharmaceuticals U.S.A., Inc.3$66
Pharmacosmos Therapeutics Inc.3$65
Sobi, Inc3$62
ADC Therapeutics America, Inc.3$58
Pharmaessentia USA Corporation2$54
AVEO Pharmaceuticals, Inc.3$49
Astellas Pharma US Inc2$47
Legend Biotech USA Inc.2$39
Geron Corporation1$35
Apellis Pharmaceuticals, Inc.2$34
Alnylam Pharmaceuticals Inc.1$26
Verastem, Inc.1$24
Nuvation Bio Inc.1$24
Agios Pharmaceuticals, Inc.1$22
Azurity Pharmaceuticals, Inc.1$19
CTI Biopharma Corp.1$19
G1 Therapeutics, Inc.1$18
Novo Nordisk1$16
Clovis Oncology, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$583,985 in reported general payments places this provider in the 95th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$39,572
Medicare patients
133
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate13$224,428
Prochlorperazine Maleate18$325
Dexamethasone18$253
Lidocaine-PrilocaineLidocaine/Prilocaine11$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$136,909$224,42813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →